Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of enzalutamide therapy in prostate cancer
jRCT2031220674Phase 2Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- May 2023
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of enzalutamide in prostate cancer (PCa) (3 arms), sponsored by Astellas Pharma. Started May 2023; status: active, not recruiting.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2031220674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220674.